bioihbjkbjnl/mcl2 huggingface dataset:
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
MeSH terms: Leukemia; Leukemia, Lymphoid; Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Dasatinib
Intervention description: Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
Intervention MeSH terms: Dasatinib
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 15.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: dasatinib; BMS-354825; CLL; SLL; LYN kinase

Summary:

      The purpose of this research study is to see if Dasatinib is effective and safe to give to
      people with relapsed chronic lymphocytic leukemia (CLL) and to determine the effects of the
      drug on LYN kinase activity in blood and bone marrow. Recent research shows that a key enzyme
      in CLL cells is responsible for cell survival. This enzyme is called LYN kinase. Laboratory
      studies show that inhibition of LYN kinase in CLL cells results in the death to CLL cells.
      Dasatinib has the ability to inhibit LYN kinase and, therefore, should have some effect on
      CLL cells.
    

Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  CLL/SLL with cells positive by flow cytometry (or immunostaining) for CD19, CD23 and
             CD. Patients may be CD23 negative as long as they are also cyclin D1 negative.

          -  Must have failed at least 1 prior fludarabine containing regimen or have failed at
             least 2 non-fludarabine containing regimens or have a contraindication to fludarabine
             use

          -  ECOG performance status of 2 or better

          -  Adequate organ function to tolerate chemotherapy

          -  Adequate method of contraception

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Uncontrolled angina within 3 months

          -  Diagnosed or suspected congenital long QT syndrome

          -  History of clinically significant ventricular arrhythmias

          -  Prolonged QTc interval on pre-entry electrocardiogram

          -  Uncontrolled hypertension

          -  Drugs that are generally accepted to have a risk of causing Torsades de Pointes

          -  Patient known to be HIV positive

          -  Known significant bleeding disorder unrelated to CLL

          -  Drugs that interfere with platelet function or coagulation must be stopped at least 7
             days prior to entry